Octreotida Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotida Teva, is a somatostatin analog presented as a strength/form for injection use. It treats hormone‑secreting tumors and related disorders in adults. GNH USA supplies Octreotida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Octreotida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Octreotide acetate is used in endocrine‑related conditions that involve excess hormone secretion.

- Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Neuroendocrine tumors: controls symptoms such as flushing and diarrhea associated with carcinoid syndrome. - Variceal bleeding: lowers portal pressure to help prevent re‑bleeding after an acute episode. - Thymoma‑associated hypoglycaemia: stabilises blood glucose by inhibiting insulin release. - Diagnostic imaging: enhances somatostatin receptor scintigraphy for tumor localisation. - Post‑operative management: used to suppress hormone recurrence after surgical removal of hormone‑producing tumours.

Octreotide acetate may cause a range of adverse reactions, most of which are mild to moderate and reversible.

Common Side Effects: - Nausea and vomiting - Abdominal pain or cramping - Diarrhoea or loose stools - Injection site erythema or discomfort - Headache - Flushing - Fatigue

Serious or Rare Side Effects: - Gallbladder sludge or gallstones - Severe hyperglycaemia or hypoglycaemia - Cardiac arrhythmias - Acute pancreatitis - Allergic reactions including anaphylaxis - Hepatic dysfunction

Octreotide acetate should be used with careful clinical monitoring and appropriate patient education.

- Renal impairment: adjust dosing and monitor renal function. - Hepatic dysfunction: assess liver enzymes before initiation. - Diabetes mellitus: monitor blood glucose closely, as the drug can affect glycaemic control. - Cardiovascular disease: observe for brady‑c​    ... - Pregnancy  ...   ...  ...  …  …  …  … ...  … … …  …